A STUDY OF TASELISIB + FULVESTRANT VERSUS PLACEBO + FULVESTRANT IN PARTICIPANTS WITH ADVANCED OR METASTATIC BREAST CANCER WHO HAVE DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY: